BRAIN Biotech Valuation

Is BNND undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of BNND when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate BNND's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate BNND's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for BNND?

Key metric: As BNND is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for BNND. This is calculated by dividing BNND's market cap by their current revenue.
What is BNND's PS Ratio?
PS Ratio	2.7x
Sales	€47.53m
Market Cap	€130.21m

BNND key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	2.5x
Enterprise Value/EBITDA	-51.2x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does BNND's PS Ratio compare to its peers?

The above table shows the PS ratio for BNND vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	0.7x
TET Treatt	1.8x	7.2%	UK£255.9m
SYNT Synthomer	0.1x	5.0%	UK£268.2m
IOF Iofina	0.9x	9.8%	UK£36.5m
CAR Carclo	0.2x	7.0%	UK£23.9m
BNND BRAIN Biotech	2.7x	11.9%	€130.2m

Price-To-Sales vs Peers: BNND is good value based on its Price-To-Sales Ratio (2.7x) compared to the peer average (3.1x).

Price to Sales Ratio vs Industry

How does BNND's PS Ratio compare vs other companies in the GB Chemicals Industry?

6 Companies	Price / Sales	Estimated Growth	Market Cap
JMAT Johnson Matthey	0.2x	-50.4%	US$3.22b
SYNT Synthomer	0.1x	5.0%	US$336.13m
CAR Carclo	0.2x	7.0%	US$29.99m
HEIQ HeiQ	0.2x	n/a	US$9.61m

6 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: BNND is expensive based on its Price-To-Sales Ratio (2.7x) compared to the UK Chemicals industry average (1.2x).

Price to Sales Ratio vs Fair Ratio

What is BNND's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BNND PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	2.7x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate BNND's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Zignago Vetro

€861.8m

Engages in the production, marketing, and sale of hollow glass containers in Italy, rest of Europe, and internationally.

0NNC

€9.58

-2.5%

-24.6%

Altri SGPS

€1.0b

Produces and sells cellulosic fibers and energy in Portugal and internationally.

0DJV

€5.00

-3.5%

4.4%

TFF Group

€687.3m

Manufactures and distributes barrels and wood products for the aging of wines and alcohols in France, rest of Europe, the United States, Asia, and internationally.

0IH4

€31.20

-1.0%

-25.5%